165 extracellular microRNA biomarkers related to 20+ cancer diseases have been identified by QuarkBio's big data analytics team. With these targeted biomarkers, researchers in the field of oncology can perform a concise screening of the biomarkers related to the cancer they are researching, using a time-saving and cost-effective method to develop their own panel.

List of miRNA Targets

miRNA+ IOPredict

By utilizing a select group of microRNA biomarkers, QuarkBio hopes to predict a cancer patient's response to immunotherapy. Currently, only about 30% of cancer patients undergoing immunotherapy responds well to the treatment - there is no way of telling beforehand whether a cancer patient falls into the responsive group or not. Therefore, with miIOPredict, we hope to provide a screening test to indicate which patient is suited for immunotherapy.

miRNA+ Cancer

miOncoCheck acts as an early detection tool for eight types of cancer by looking at microRNA expression in the bloodstream. With miOncoCheck, QuarkBio hopes to detect cancer's presence before physical signs can be seen through comprehensive scans.

miRNA+ Diabetes

Secondary complications for diabetes patients typically arise after 5 years of living with the disease. Not every diabetes patient will develop secondary complications, but currently there is no way to predict which patient will develop the complications ahead of time for preventive treatment. QuarkBio is looking at microRNA biomarkers that can potentially predict a diabetes patient’s risk of developing secondary complications and also the timeline of when the complications will arise. Currently, we are focused specifically on kidney and retinal complications.


Cardiovascular diseases are the leading cause of death globally, yet it is estimated that 90% of CVD is preventable. Together with our collaborators, we are developing a PanelChip™ exploring the potential of small RNA in the early stage diagnosis of CVD. The assay is non-invasive, which allows monitoring of the disease in a robust manner.